Related Experiment Videos
Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study
1Division of Medical Oncology/Hematology, Toronto Sunnybrook, Regional Cancer Centre, Toronto, Canada.
Oncology (Williston Park, N.Y.)
|June 9, 2001
Summary
The MA.21 trial is evaluating adjuvant chemotherapy regimens, including CEF, AC-->T, and EC-->T, for breast cancer patients. This research aims to optimize adjuvant therapy for improved patient outcomes.
Area of Science:
- Oncology
- Clinical Trials
- Pharmacology
Background:
- Adjuvant chemotherapy is crucial for node-positive and high-risk node-negative breast cancer.
- Previous studies suggest superiority of certain regimens over older standards like AC and CMF.
Purpose of the Study:
- To compare the efficacy of three adjuvant chemotherapy regimens in a Phase III trial.
- To advance optimal adjuvant therapy strategies for breast cancer patients.
Main Methods:
- Phase III randomized trial (MA.21) involving premenopausal and postmenopausal women (<= 60 years) with no distant metastases.
- Comparison of cyclophosphamide, epirubicin, fluorouracil (CEF) and doxorubicin, cyclophosphamide followed by paclitaxel (AC-->T).
- Inclusion of a third arm: dose-dense, dose-intense epirubicin, cyclophosphamide followed by paclitaxel (EC-->T).
Main Results:
- Trial results supporting the selection of CEF, AC-->T, and EC-->T regimens are reviewed.
- Evidence suggests these regimens may be superior to older standards like AC and CMF.
Conclusions:
- The MA.21 trial is designed to determine the optimal adjuvant chemotherapy regimen for breast cancer.
- Findings will contribute to advancing treatment strategies and improving patient survival.